Search PubMed⌕ Search

PubMed · 2673445

Erythropoietin.

Abstract

Erythropoietin is a glycoprotein hormone produced in the kidneys and to a lesser extent in the liver which regulates the proliferation and differentiation of erythroid progenitor cells. The gene for erythropoietin is well conserved and the hormone is always present in the plasma even in the renoprival state, emphasizing its important physiologic role. Failure to produce adequate quantities of erythropoietin leads to severe anemia, a situation most often encountered in patients with end stage renal disease. With the application of recombinant DNA technology, the gene for erythropoietin has been molecularly cloned, sequenced and expressed in a biologically active form in mammalian cells. In recent clinical trials, the recombinant hormone has been demonstrated to correct anemia in patients with severe end stage renal disease and alleviate their transfusion requirements.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J L Spivak. 1989. Erythropoietin.. https://doi.org/10.1016/0268-960x(89)90008-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Safety considerations for erythropoietin treatment in patients with cancer.

Cancer-related anaemia, which affects many patients with cancer, can effectively be treated by erythropoietic proteins. Erythropoietic proteins increase haemoglobin levels, reduce the risk for transfusions and also improve the quality of life of patients. When used according to published practice guidelines, these proteins benefit many patients and are generally well tolerated. Important side effects are hypertension and thromboembolic events, either of which occurs in < 10% of the patients. Administration only in anaemic patients, avoidance of target haemoglobin levels > 130 g/l, proper dose adjustments and close monitoring during treatment will ensure the clinical safety of these proteins. However, the association between erythropoietic proteins and outcome of anticancer therapy, including survival, requires further study.

Erythropoietin↗